Cleavage of the HPV16 minor capsid protein L2 during virion morphogenesis ablates the requirement for cellular furin during de novo infection

Viruses

Volumn 7, Issue 11, 2015, Pages 5813-5830

  Cruz, Linda ^a   Biryukov, Jennifer ^a   Conway, Michael J ^a   Meyers, Craig ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Furin; HPV16; Human papillomavirus (HPV); J0101; PACS

Indexed keywords

CAPSID PROTEIN; FURIN; PROPROTEIN CONVERTASE 1; L2 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DE NOVO INFECTION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN TISSUE; IMMUNOFLUORESCENCE; INFECTION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN CLEAVAGE; REAL TIME POLYMERASE CHAIN REACTION; VIRION; VIRUS MORPHOGENESIS; WESTERN BLOTTING; ANIMAL; CELL LINE; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PHYSIOLOGY; VIRUS ENTRY;

ANIMALS; CAPSID PROTEINS; CELL LINE; FURIN; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; VIRUS INTERNALIZATION;

EID: 84946925895     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7112910     Document Type: Article

References (82)

1. Schiffman, M.; Kjaer, S.K. Natural history of anogenital human papillomavirus infection and neoplasia. J. Natl. Cancer Inst. Monogr. 2003, 31, 14-19. [CrossRef] [PubMed]
2. Zur Hausen, H. Papillomaviruses in the causation of human cancers-A brief historical account. Virology 2009, 384, 260-265. [CrossRef] [PubMed]
3. Baker, T.S.; Newcomb, W.W.; Olson, N.H.; Cowsert, L.M.; Olson, C.; Brown, J.C. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys. J. 1991, 60, 1445-1456. [CrossRef]
4. Chen, X.S.; Garcea, R.L.; Goldberg, I.; Casini, G.; Harrison, S.C. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol. Cell 2000, 5, 557-567. [CrossRef]
5. Knappe, M.; Bodevin, S.; Selinka, H.C.; Spillmann, D.; Streeck, R.E.; Chen, X.S.; Lindahl, U.; Sapp, M. Surface-exposed amino acid residues of hpv16 L1 protein mediating interaction with cell surface heparan sulfate. J. Biol. Chem. 2007, 282, 27913-27922. [CrossRef] [PubMed]
6. Volpers, C.; Unckell, F.; Schirmacher, P.; Streeck, R.E.; Sapp, M. Binding and internalization of human papillomavirus type 33 virus-like particles by eukaryotic cells. J. Virol. 1995, 69, 3258-3264. [PubMed]
7. Trus, B.L.; Roden, R.B.; Greenstone, H.L.; Vrhel, M.; Schiller, J.T.; Booy, F.P. Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 Å resolution. Nat. Struct. Biol. 1997, 4, 413-420. [CrossRef] [PubMed]
8. Buck, C.B.; Cheng, N.; Thompson, C.D.; Lowy, D.R.; Steven, A.C.; Schiller, J.T.; Trus, B.L. Arrangement of L2 within the papillomavirus capsid. J. Virol. 2008, 82, 5190-5197. [PubMed]
9. Wang, J.W.; Roden, R.B. L2, the minor capsid protein of papillomavirus. Virology 2013, 445, 175-186. [CrossRef] [PubMed]
10. Roden, R.B.; Greenstone, H.L.; Kirnbauer, R.; Booy, F.P.; Jessie, J.; Lowy, D.R.; Schiller, J.T. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 1996, 70, 5875-5883. [PubMed]
11. Zhao, K.N.; Sun, X.Y.; Frazer, I.H.; Zhou, J. Dna packaging by L1 and L2 capsid proteins of bovine papillomavirus type 1. Virology 1998, 243, 482-491. [CrossRef] [PubMed]
12. Ishii, Y.; Ozaki, S.; Tanaka, K.; Kanda, T. Human papillomavirus 16 minor capsid protein L2 helps capsomeres assemble independently of intercapsomeric disulfide bonding. Virus Genes 2005, 31, 321-328. [CrossRef] [PubMed]
13. Florin, L.; Sapp, M.; Spoden, G.A. Host-cell factors involved in papillomavirus entry. Med. Microbiol. Immunol. 2012, 201, 437-448. [CrossRef] [PubMed]
14. Kawana, Y.; Kawana, K.; Yoshikawa, H.; Taketani, Y.; Yoshiike, K.; Kanda, T. Human papillomavirus type 16 minor capsid protein L2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. J. Virol. 2001, 75, 2331-2336. [PubMed]
15. Yang, R.; Day, P.M.; Yutzy, W.H.T.; Lin, K.Y.; Hung, C.F.; Roden, R.B. Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J. Virol. 2003, 77, 3531-3541. [CrossRef]
16. Woodham, A.W.; da Silva, D.M.; Skeate, J.G.; Raff, A.B.; Ambroso, M.R.; Brand, H.E.; Isas, J.M.; Langen, R.; Kast, W.M. The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS ONE 2012, 7, e43519. [CrossRef] [PubMed]
17. Kawana, K.; Matsumoto, K.; Yoshikawa, H.; Taketani, Y.; Kawana, T.; Yoshiike, K.; Kanda, T. A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2. Virology 1998, 245, 353-359. [CrossRef] [PubMed]
18. Bienkowska-Haba, M.; Patel, H.D.; Sapp, M. Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog. 2009, 5, e1000524. [CrossRef] [PubMed]
19. Bergant Marusic, M.; Ozbun, M.A.; Campos, S.K.; Myers, M.P.; Banks, L. Human papillomavirus L2 facilitates viral escape from late endosomes via sorting nexin 17. Traffic 2012, 13, 455-467. [CrossRef] [PubMed]
20. Bossis, I.; Roden, R.B.; Gambhira, R.; Yang, R.; Tagaya, M.; Howley, P.M.; Meneses, P.I. Interaction of tsnare syntaxin 18 with the papillomavirus minor capsid protein mediates infection. J. Virol. 2005, 79, 6723-6731. [CrossRef] [PubMed]
21. Yang, R.; Yutzy, W.H.T.; Viscidi, R.P.; Roden, R.B. Interaction of L2 with β-actin directs intracellular transport of papillomavirus and infection. J. Biol. Chem. 2003, 278, 12546-12553. [CrossRef] [PubMed]
22. Florin, L.; Becker, K.A.; Lambert, C.; Nowak, T.; Sapp, C.; Strand, D.; Streeck, R.E.; Sapp, M. Identification of a dynein interacting domain in the papillomavirus minor capsid protein L2. J. Virol. 2006, 80, 6691-6696. [CrossRef] [PubMed]
23. Day, P.M.; Roden, R.B.; Lowy, D.R.; Schiller, J.T. The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. J. Virol. 1998, 72, 142-150. [PubMed]
24. Kondo, K.; Ishii, Y.; Mori, S.; Shimabukuro, S.; Yoshikawa, H.; Kanda, T. Nuclear location of minor capsid protein L2 is required for expression of a reporter plasmid packaged in HPV51 pseudovirions. Virology 2009, 394, 259-265. [CrossRef] [PubMed]
25. Richards, R.M.; Lowy, D.R.; Schiller, J.T.; Day, P.M. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl. Acad. Sci. USA 2006, 103, 1522-1527. [CrossRef] [PubMed]
26. Kines, R.C.; Thompson, C.D.; Lowy, D.R.; Schiller, J.T.; Day, P.M. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc. Natl. Acad. Sci. USA 2009, 106, 20458-20463. [CrossRef] [PubMed]
27. Yu, I.M.; Zhang, W.; Holdaway, H.A.; Li, L.; Kostyuchenko, V.A.; Chipman, P.R.; Kuhn, R.J.; Rossmann, M.G.; Chen, J. Structure of the immature dengue virus at low ph primes proteolytic maturation. Science 2008, 319, 1834-1837. [CrossRef] [PubMed]
28. Stadler, K.; Allison, S.L.; Schalich, J.; Heinz, F.X. Proteolytic activation of tick-borne encephalitis virus by furin. J. Virol. 1997, 71, 8475-8481. [PubMed]
29. Nakayama, K. Furin: A mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem. J. 1997, 327(Pt. 3), 625-635. [CrossRef] [PubMed]
30. Nagai, Y. Protease-dependent virus tropism and pathogenicity. Trends Microbiol. 1993, 1, 81-87. [CrossRef]
31. Doorbar, J.; Quint,W.; Banks, L.; Bravo, I.G.; Stoler, M.; Broker, T.R.; Stanley, M.A. The biology and life-cycle of human papillomaviruses. Vaccine 2012, 30 (Suppl. 5), F55-F70. [CrossRef] [PubMed]
32. Buck, C.B.; Pastrana, D.V.; Lowy, D.R.; Schiller, J.T. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 2004, 78, 751-757. [CrossRef] [PubMed]
33. Raff, A.B.; Woodham, A.W.; Raff, L.M.; Skeate, J.G.; Yan, L.; da Silva, D.M.; Schelhaas, M.; Kast, W.M. The evolving field of human papillomavirus receptor research: A review of binding and entry. J. Virol. 2013, 87, 6062-6072. [CrossRef] [PubMed]
34. Day, P.M.; Lowy, D.R.; Schiller, J.T. Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 2003, 307, 1-11. [CrossRef]
35. Embers, M.E.; Budgeon, L.R.; Culp, T.D.; Reed, C.A.; Pickel, M.D.; Christensen, N.D. Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins. Vaccine 2004, 22, 670-680. [PubMed]
36. Gambhira, R.; Karanam, B.; Jagu, S.; Roberts, J.N.; Buck, C.B.; Bossis, I.; Alphs, H.; Culp, T.; Christensen, N.D.; Roden, R.B. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J. Virol. 2007, 81, 13927-13931. [PubMed]
37. White, W.I.; Wilson, S.D.; Palmer-Hill, F.J.; Woods, R.M.; Ghim, S.J.; Hewitt, L.A.; Goldman, D.M.; Burke, S.J.; Jenson, A.B.; Koenig, S.; et al. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J. Virol. 1999, 73, 4882-4889. [PubMed]
38. Kirnbauer, R.; Booy, F.; Cheng, N.; Lowy, D.R.; Schiller, J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 1992, 89, 12180-12184. [PubMed]
39. Biryukov, J.; Meyers, C. Papillomavirus infectious pathways: A comparison of systems. Viruses 2015, 7, 4303-4325. [CrossRef] [PubMed]
40. Conway, M.J.; Alam, S.; Ryndock, E.J.; Cruz, L.; Christensen, N.D.; Roden, R.B.; Meyers, C. Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J. Virol. 2009, 83, 10515-10526. [CrossRef] [PubMed]
41. Conway, M.J.; Cruz, L.; Alam, S.; Christensen, N.D.; Meyers, C. Differentiation-dependent interpentameric disulfide bond stabilizes native human papillomavirus type 16. PLoS ONE 2011, 6, e22427. [CrossRef] [PubMed]
42. Buck, C.B.; Thompson, C.D.; Pang, Y.Y.; Lowy, D.R.; Schiller, J.T. Maturation of papillomavirus capsids. J. Virol. 2005, 79, 2839-2846. [CrossRef] [PubMed]
43. Song, H.; Moseley, P.L.; Lowe, S.L.; Ozbun, M.A. Inducible heat shock protein 70 enhances HPV31 viral genome replication and virion production during the differentiation-dependent life cycle in human keratinocytes. Virus Res. 2010, 147, 113-122. [CrossRef] [PubMed]
44. Chromy, L.R.; Pipas, J.M.; Garcea, R.L. Chaperone-mediated in vitro assembly of polyomavirus capsids. Proc. Natl. Acad. Sci. USA 2003, 100, 10477-10482. [PubMed]
45. Chromy, L.R.; Oltman, A.; Estes, P.A.; Garcea, R.L. Chaperone-mediated in vitro disassembly of polyoma- and papillomaviruses. J. Virol. 2006, 80, 5086-5091. [CrossRef] [PubMed]
46. Conway, M.J.; Cruz, L.; Alam, S.; Christensen, N.D.; Meyers, C. Cross-neutralization potential of native human papillomavirus N-terminal L2 epitopes. PLoS ONE 2011, 6, e16405. [CrossRef] [PubMed]
47. Day, P.M.; Gambhira, R.; Roden, R.B.; Lowy, D.R.; Schiller, J.T. Mechanisms of human papillomavirus type 16 neutralization by L2 cross-neutralizing and L1 type-specific antibodies. J. Virol. 2008, 82, 4638-4646. [CrossRef] [PubMed]
48. Cruz, L.; Meyers, C. Differential dependence on host cell glycosaminoglycans for infection of epithelial cells by high-risk HPV types. PLoS ONE 2013, 8, e68379. [CrossRef] [PubMed]
49. Richards, K.F.; Mukherjee, S.; Bienkowska-Haba, M.; Pang, J.; Sapp, M. Human papillomavirus species-specific interaction with the basement membrane-resident non-heparan sulfate receptor. Viruses 2014, 6, 4856-4879. [CrossRef] [PubMed]
50. Day, P.M.; Lowy, D.R.; Schiller, J.T. Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids. J. Virol. 2008, 82, 12565-12568. [CrossRef] [PubMed]
51. Roden, R.B.; Armstrong, A.; Haderer, P.; Christensen, N.D.; Hubbert, N.L.; Lowy, D.R.; Schiller, J.T.; Kirnbauer, R. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J. Virol. 1997, 71, 6247-6252. [PubMed]
52. Christensen, N.D.; Dillner, J.; Eklund, C.; Carter, J.J.; Wipf, G.C.; Reed, C.A.; Cladel, N.M.; Galloway, D.A. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996, 223, 174-184. [CrossRef] [PubMed]
53. Pastrana, D.V.; Buck, C.B.; Pang, Y.Y.; Thompson, C.D.; Castle, P.E.; FitzGerald, P.C.; Kruger Kjaer, S.; Lowy, D.R.; Schiller, J.T. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004, 321, 205-216. [CrossRef] [PubMed]
54. Jean, F.; Stella, K.; Thomas, L.; Liu, G.; Xiang, Y.; Reason, A.J.; Thomas, G. Alpha1-antitrypsin portland, a bioengineered serpin highly selective for furin: Application as an antipathogenic agent. Proc. Natl. Acad. Sci. USA 1998, 95, 7293-7298. [CrossRef] [PubMed]
55. Gordon, V.M.; Klimpel, K.R.; Arora, N.; Henderson, M.A.; Leppla, S.H. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect. Immun. 1995, 63, 82-87. [PubMed]
56. Pearton, D.J.; Nirunsuksiri,W.; Rehemtulla, A.; Lewis, S.P.; Presland, R.B.; Dale, B.A. Proprotein convertase expression and localization in epidermis: Evidence for multiple roles and substrates. Exp. Dermatol. 2001, 10, 193-203. [CrossRef] [PubMed]
57. Lin, Z.; Yemelyanova, A.V.; Gambhira, R.; Jagu, S.; Meyers, C.; Kirnbauer, R.; Ronnett, B.M.; Gravitt, P.E.; Roden, R.B. Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2. Am. J. Pathol. 2009, 174, 136-143. [CrossRef] [PubMed]
58. Doorbar, J.; Gallimore, P.H. Identification of proteins encoded by the L1 and L2 open reading frames of human papillomavirus 1a. J. Virol. 1987, 61, 2793-2799. [PubMed]
59. Jin, X.W.; Cowsert, L.M.; Pilacinski,W.P.; Jenson, A.B. Identification of L2 open reading frame gene products of bovine papillomavirus type 1 using monoclonal antibodies. J. General Virol. 1989, 70, 1133-1140.
60. Komly, C.A.; Breitburd, F.; Croissant, O.; Streeck, R.E. The L2 open reading frame of human papillomavirus type 1a encodes a minor structural protein carrying type-specific antigens. J. Virol. 1986, 60, 813-816. [PubMed]
61. Rose, R.C.; Bonnez, W.; Strike, D.G.; Reichman, R.C. Expression of the full-length products of the human papillomavirus type 6b (HPV-6b) and HPV-11 L2 open reading frames by recombinant baculovirus, and antigenic comparisons with HPV-11 whole virus particles. J. General Virol. 1990, 71, 2725-2729. [CrossRef] [PubMed]
62. McLaughlin-Drubin, M.E.; Wilson, S.; Mullikin, B.; Suzich, J.; Meyers, C. Human papillomavirus type 45 propagation, infection, and neutralization. Virology 2003, 312, 1-7. [CrossRef]
63. Meyers, C.; Mayer, T.J.; Ozbun, M.A. Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral dna. J. Virol. 1997, 71, 7381-7386. [PubMed]
64. Meyers, C.; Frattini, M.G.; Hudson, J.B.; Laimins, L.A. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 1992, 257, 971-973. [CrossRef] [PubMed]
65. Madison, K.C.; Sando, G.N.; Howard, E.J.; True, C.A.; Gilbert, D.; Swartzendruber, D.C.; Wertz, P.W. Lamellar granule biogenesis: A role for ceramide glucosyltransferase, lysosomal enzyme transport, and the golgi. J. Investig. Dermatol. Symp. Proc. 1998, 3, 80-86. [CrossRef] [PubMed]
66. Elias, P.M.; Cullander, C.; Mauro, T.; Rassner, U.; Komuves, L.; Brown, B.E.; Menon, G.K. The secretory granular cell: The outermost granular cell as a specialized secretory cell. J. Investig. Dermatol. Symp. Proc. 1998, 3, 87-100. [CrossRef] [PubMed]
67. Madison, K.C.; Howard, E.J. Ceramides are transported through the golgi apparatus in human keratinocytes in vitro. J. Investig. Dermatol. 1996, 106, 1030-1035. [CrossRef] [PubMed]
68. Bryan, J.T.; Brown, D.R. Transmission of human papillomavirus type 11 infection by desquamated cornified cells. Virology 2001, 281, 35-42. [CrossRef] [PubMed]
69. Pereira, R.; Hitzeroth, I.I.; Rybicki, E.P. Insights into the role and function of L2, the minor capsid protein of papillomaviruses. Arch. Virol. 2009, 154, 187-197. [CrossRef] [PubMed]
70. Zhou, J.; Sun, X.Y.; Louis, K.; Frazer, I.H. Interaction of human papillomavirus (HPV) type 16 capsid proteins with HPV DNA requires an intact L2 N-terminal sequence. J. Virol. 1994, 68, 619-625. [PubMed]
71. Culp, T.D.; Budgeon, L.R.; Marinkovich, M.P.; Meneguzzi, G.; Christensen, N.D. Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells. J. Virol. 2006, 80, 8940-8950. [CrossRef] [PubMed]
72. Cerqueira, C.; Liu, Y.; Kuhling, L.; Chai, W.; Hafezi, W.; van Kuppevelt, T.H.; Kuhn, J.E.; Feizi, T.; Schelhaas, M. Heparin increases the infectivity of human papillomavirus type 16 independent of cell surface proteoglycans and induces L1 epitope exposure. Cell. Microbiol. 2013. [CrossRef] [PubMed]
73. Sapp, M.; Bienkowska-Haba, M. Viral entry mechanisms: Human papillomavirus and a long journey from extracellular matrix to the nucleus. Febs. J. 2009, 276, 7206-7216. [CrossRef] [PubMed]
74. Spoden, G.; Kuhling, L.; Cordes, N.; Frenzel, B.; Sapp, M.; Boller, K.; Florin, L.; Schelhaas, M. Human papillomavirus types 16, 18, and 31 share similar endocytic requirements for entry. J. Virol. 2013, 87, 7765-7773. [CrossRef] [PubMed]
75. Schelhaas, M.; Shah, B.; Holzer, M.; Blattmann, P.; Kuhling, L.; Day, P.M.; Schiller, J.T.; Helenius, A. Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS Pathog. 2012, 8, e1002657. [CrossRef] [PubMed]
76. Smith, J.L.; Campos, S.K.; Wandinger-Ness, A.; Ozbun, M.A. Caveolin-1-dependent infectious entry of human papillomavirus type 31 in human keratinocytes proceeds to the endosomal pathway for ph-dependent uncoating. J. Virol. 2008, 82, 9505-9512. [PubMed]
77. Bousarghin, L.; Touze, A.; Sizaret, P.Y.; Coursaget, P. Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells. J. Virol. 2003, 77, 3846-3850. [CrossRef] [PubMed]
78. Hindmarsh, P.L.; Laimins, L.A. Mechanisms regulating expression of the HPV 31 L1 and L2 capsid proteins and pseudovirion entry. Virol. J. 2007, 4, 19. [CrossRef] [PubMed]
79. Surviladze, Z.; Dziduszko, A.; Ozbun, M.A. Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathog. 2012, 8, e1002519. [PubMed]
80. Buck, C.B.; Pastrana, D.V.; Lowy, D.R.; Schiller, J.T. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol. Med. 2005, 119, 445-462. [PubMed]
81. Leder, C.; Kleinschmidt, J.A.;Wiethe, C.; Muller, M. Enhancement of capsid gene expression: Preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J. Virol. 2001, 75, 9201-9209. [CrossRef] [PubMed]
82. Culp, T.D.; Cladel, N.M.; Balogh, K.K.; Budgeon, L.R.; Mejia, A.F.; Christensen, N.D. Papillomavirus particles assembled in 293tt cells are infectious in vivo. J. Virol. 2006, 80, 11381-11384. [CrossRef] [PubMed]